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Abstract: The acute effects of intracellular phosphate depletion and hypophosphatemia 
on organs and tissues in and during recovery from diabetic ketoacidosis (DKA) have been 
reviewed. When insufficient phosphate and/or oxygen are available for high energy phosphate 
synthesis, cell homeostasis cannot be maintained and cell integrity may be impaired. The 
clinical consequences are recognized as occasional cause of morbidity and mortality. Although 
phosphate repletion has not been routinely recommended in the treatment of DKA, physicians 
should be aware of these clinical conditions and phosphate repletion in such situations should 
be considered.
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Introduction
The phosphorus-depletion syndrome has been known to veterinary surgeons for 
many decades. In the 1960s, the phosphorus-depletion syndrome was first described 
in Man by Bloom and Flinchum,1 who also reported a case of muscle weakness 
and osteomalacia in a patient with excessive ingestion of nonabsorbable antacids 
  containing   magnesium–aluminum hydroxides, which limit gastrointestinal   absorption 
of   phosphorus. Lotz et al2 presented the effects of experimental phosphorus   depletion 
in three normal volunteers and in three patients with parathyroid dysfunction during 
  prolonged treatment with antacids. They observed a syndrome with hypophosphatemia, 
increased absorption of skeletal calcium and phosphorus, and clinical symptoms such 
as   debilitation, anorexia, weakness, and bone pain. These reports were followed by 
more extensive research and reviews.3–5
Recently, we have presented the evidence of the occurrence of a paradoxical imbal-
ance in phosphate metabolism from the early onset of diabetes mellitus and have indi-
cated that this imbalance may lead to a reduction of high energy phosphates and tissue 
hypoxia. These changes take place in cells and tissues in which the entry of glucose is 
not controlled by insulin and occur particularly in poorly regulated, though ambulatory 
diabetic patients in whom long-term vascular complications are more likely.6,7
In this article, we review the evidence suggesting the role of cellular   phosphorus 
depletion and hypophosphatemia in the development of acute, occasionally life-
  threatening complications in hospitalized patients during treatment of diabetic 
  ketoacidosis (DKA). The review is based on a search primarily using Medline 
(PubMed) and secondarily Embase, as well as information from reference lists.Diabetes, Metabolic Syndrome and Obesity:Targets and Therapy  2010:3 submit your manuscript | www.dovepress.com
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Inorganic phosphate  
and ketoacidosis
DKA is associated with various degrees of intracellular phos-
phate depletion, partially because of a shift of phosphorus 
from the intracellular to the extracellular compartments and 
because of prolonged and excessive hyperphosphaturia.6 
During DKA, the plasma inorganic phosphate (Pi) may 
be normal or even elevated despite intracellular phosphate 
depletion. Initial treatment with intravenous fluid and insulin 
allows sudden entry of plasma glucose and phosphate into 
the insulin-sensitive tissues for cellular phosphorylation, 
and plasma Pi may be drastically decreased. Riley et al8 
demonstrated that insulin-induced hypophosphatemia is 
dose dependent and significant hypophosphatemia may occur 
within 30 minutes following administration of insulin. In the 
clinical situation, “refeeding” hypophosphatemia is usually 
first recognized at the second day of treatment and may last 
for a week depending on the degree of intracellular phosphate 
depletion and the replacement rate of intravenous fluid and 
insulin. In contrast to plasma Pi, the degree of intracellular 
phosphate cannot be clinically determined on admission 
because this parameter depends on the preceding dietary 
intake of phosphorus, the duration of the ketotic state, and 
the presence of associated factors, such as stress, infections, 
and duration of insufficient insulin intake.
Cellular phosphate depletion and associated hypophos-
phatemia, if severe, may give rise to signs and symptoms from 
many organ systems and is recognized as a cause of mor-
bidity and mortality in DKA. When insufficient phosphate 
and oxygen are available for adenosine triphosphate (ATP) 
synthesis, cell homeostasis cannot be maintained and may 
result in cell lyses.9 Because randomized studies of patients 
with ketoacidosis on phosphate therapy did not affect the 
duration of DKA, dose of insulin required to the acidosis, 
abnormal muscle enzyme levels, glucose disappearance 
rate, or morbidity and mortality, phosphate therapy is not an 
essential part of the therapy for DKA in most patients.10–13 
However, although phosphate repletion is not recommended 
as an adjuvant in the treatment of DKA,14 physicians should 
be aware of the clinical manifestations to ensure no delay in 
phosphate repletion in such situations.
Hematological manifestations
Phosphorus plays an important role in several aspect of 
cellular metabolism, including ATP synthesis, which is the 
source of energy for many cellular reactions, and red cell 
2,3-diphosphoglycerate (2,3-DPG), which regulates the dis-
sociation of oxygen from hemoglobin. Studies have shown 
low levels of 2,3-DPG and ATP in red blood cells and the fact 
that low levels of intraerythrocytic phosphate inhibit whereas 
high levels stimulate red cell glycolysis.15–17 During DKA, 
the effect of increased hydrogen ions on the oxyhemoglobin 
dissociation curve (ODC) is balanced by the diminished 
2,3-DPG. However, after correction of acidosis, the low 
2,3-DPG level shifts the ODC markedly to the left with a 
corresponding decrease in the ODC P50 (oxygen tension at 
50% oxygen saturation). In close correlation with plasma 
Pi concentration, it may take up to 1 week for 2,3-DPG to 
return to an approximately normal level, and the oxygen 
delivery to tissues will be impaired for the same period 
(  Figure 1).18–20 P50 of ODC at in vivo pH in 10 consecutive 
cases of ketoacidosis following insulin administration cor-
related closely with plasma Pi (r = 0.80; P , 0.001) and red 
cell 2,3-DPG (r = 0.94; P , 0.001).21 This deficient oxygen 
delivery influences all organs and tissues, although organs 
with high oxygen demand, such as the renal medulla, brain, 
retina, pancreas, and heart, may suffer the most.
When red cell ATP is significantly decreased, the eryth-
rocyte membrane becomes rigid, and such erythrocytes may 
be trapped in the spleen leading to hemolytic anemia.22 When 
ATP levels in the leukocytes are significantly decreased, 
their phagocytic, chemotactic, and bactericidal activities 
are reduced.23
Neurological manifestations
Encephalopathy, confusion, seizures, hallucinations, and 
coma are the clinical signs that may develop during pro-
longed, severe hypophosphatemia following treatment of 
DKA. When verified, these symptoms should be promptly 
treated with intravenous phosphate, which often result in 
dramatic recovery.24–27
Muscular manifestations
Muscular weakness is a common symptom, and   myopathy, 
even in its more severe form as rhabdomyolysis, may 
occur.28,29 Among 12 consecutively admitted ketoacidotic 
patients, we found five with asymptomatic hypermyo-
globulinemia and elevated creatine kinase isoenzyme MM, 
characteristic of rhabdomyolysis.29 Patients with DKA are 
invariably dehydrated – often severely – and restoration of 
fluid and electrolytes is of first priority. In DKA, a   remarkable 
small extraction of oxygen takes place through muscular 
and cutaneous tissues.18,30 Patients with DKA, in addition to 
dehydration, may also be in a preshock situation, which leads 
to a considerably increased release of catecholamine, mainly 
noradrenalin,31 and a redistribution of   microcirculatory flow.   Diabetes, Metabolic Syndrome and Obesity:Targets and Therapy  2010:3 submit your manuscript | www.dovepress.com
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The arterioles in the cutaneous and splanchnic areas may be 
constricted, and blood flow will be shunted through biomi-
croscopically observable arteriolar–venular   communications 
(thoroughfare channels; vascular pattern-change II) whereby 
blood flow bypasses the nutritive capillaries.32 The result-
ing ischemic hypoxia of glucose- and   phosphate-starved 
muscle cells may lead to reduced ATP, resulting in   membrane 
  disruption and allowing myoglobin and creatine kinase 
isoenzyme MM to enter into the circulation.
Myocardial manifestations
Møller et al33 presented two patients with severe DKA, 
who showed elevations of the biomarkers troponin T and 
creatine kinase MB and initial electrocardiographic changes 
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Figure 1 Pattern of changes in plasma phosphate (∆), 2,3-DPG (•), and P50 at in vivo pH on the oxyhemoglobin dissociation curve (○) in a case of diabetic ketoacidosis.   
Abbreviations: 2,3-DPG, 2,3-diphosphoglycerate; Hb, hemoglobin.Diabetes, Metabolic Syndrome and Obesity:Targets and Therapy  2010:3 submit your manuscript | www.dovepress.com
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  compatible with myocardial infarction. However, all 
  successive   investigations including coronary arteriogra-
phy were normal. The concentration of plasma Pi was not 
reported. Hypophosphatemia is known to be associated 
with low levels of cellular ATP and impairment of human 
myocardial performance.34,35
Pulmonary manifestations
Acute respiratory failure in DKA patients with severe hypo-
phosphatemia has been reported, and normally good results 
have been reported with phosphate replacement.36,37
Renal manifestations
Dehydration, volume depletion, renal hypoperfusion, and 
decreased intracellular tubular phosphate content often occur. 
Therefore, signs of renal tubular cell damage, as indicated 
by increased urinary excretion of enzymes from the brush 
border membrane such as increased urinary excretion of 
β2-microglobulin, γ-glutamyltransferase, leucine amino-
peptidase, and N-acetyl-β-d-glucosaminidase, are common. 
Cases of renal tubular acidosis have also been seen.38–40 
These tubular cell disturbances may occur despite normal 
glomerular function.
Gastrointestinal manifestations
Nonspecific hyperamylasemia and abdominal pain are 
frequent findings during and after treatment of DKA with 
significantly negative correlation with plasma Pi.41–43 In a 
study of 12 patients with ketoacidosis, salivary, pancre-
atic isoamylases, and pancreas lipase were determined. 
Hyperamylasemia was present in six patients, of which, 
five showed simultaneous increases in all three specific pan-
creatic enzymes, and one had increased salivary isoamylases 
alone. In none of the patients, the clinical course or the time-
concentration curves of pancreatic enzymes were consistent 
with acute pancreatitis.43
Discussion
Despite the prevalence of hypophosphatemia, the aforemen-
tioned acute clinical consequences are not common. Some of 
the cited references are from the period prior to the advent 
of routine, low-dose insulin administration. However, as 
indicated, the early and severe hypophosphatemia associated 
with the recovery phase of DKA seems to be related to rapid 
uptake of glucose and Pi by the insulin-sensitive cells and 
tissues following the administration of insulin and   correction 
of acidosis. In this situation, the insulin-insensitive cells 
may continue to be phosphate-starved and may suffer from 
affinity hypoxia with associated metabolic consequences. 
A   flowchart indicating the most important factors leading 
to ATP deficiency in and during recovery from DKA is 
  presented in Figure 2. Acidosis induces low red cell 2,3-DPG 
because of inhibition of phosphofructokinase and dehydra-
tion. Through redistribution of regional microcirculation 
and shunt flow, ischemic hypoxia may develop, which can 
be curtailed by rehydration.
As insulin begins to normalize glucose metabolism in the 
insulin-sensitive tissues, phosphorus enters into the cells and 
marked hypophosphatemia may develop. Hypophosphatemia 
slows the abolishment of affinity hypoxia (Figure 1). The two 
important elements, phosphorus and oxygen, for optimal 
ATP synthesis may thereby be limiting factors. Following 
the initial treatment of DKA, the cells of many organs and 
tissues may release enzymes, most likely because of this 
inhibition of energy metabolism. The resulting ATP deple-
tion may lead to fluxes of Na+, K+, and Cl− according to their 
gradients across the cellular membranes and with swelling of 
cells. Subsequently, Ca2+ may leak into the cells, activating 
phospholipases and the formation of eicosanoids, affecting 
the cytoskeleton, and initiating oxidant formation. The pre-
cise “point of no return” is unknown, but uncontrolled Ca2+ 
activity in the cell probably has an important role in initiating 
irreversible cell damage.44
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leading to normal pH Ischemic hypoxia
Redistribution &
shunt flow
Dehydration
Diabetic
ketoacidosis
Red cell 2, 3-DPG
Figure  2  A  flowchart  indicating  the  most  important  factors  leading  to  ATP 
deficiency in and during recovery from diabetic ketoacidosis. 
Abbreviations: ATP, adenosine triphosphate; ODC, oxyhemoglobin dissociation 
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Diabetic patients with clinical symptoms of phosphate 
depletion and severe hypophosphatemia (,1.0 mg/dL); 
  (tetany, seizures, prolonged unconsciousness, rhabdomyoly-
sis, respiratory failure, and ventricular tachycardia) and those 
with one or more defective oxygen transport mechanisms 
(severe anemia, chronic obstructive pulmonary disease, and 
congestive heart failure) should be repleted with phosphate. 
The symptoms and signs of phosphate depletion can vary, 
are nonspecific, and are usually seen in patients with mul-
tiple problems. This makes it difficult to identify phosphate 
depletion as the cause of the clinical manifestations.45 The 
response to phosphorus repletion with solutions of Pi is 
usually effective and safe.46 The organic phosphate, fructose 
1,6-diphosphate (FDP), a key intermediate in glycolysis and 
the product of the major regulatory enzyme in the pathway 
(phosphofructokinase), has been suggested as an alternative. 
FDP acts as human bioenergy and can transport phosphorous 
into cells and, in a single report, FDP was shown to be more 
effective and safe than plasma Pi in restoring red cell 2,3-
DPG in patients.47 Further studies on this subject are clearly 
needed before any conclusion can be reached.
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